

INDEX

- ablation, 59–60, 82, 236
 abortion, 108, 172–73, *See also*
 Planned Parenthood clinics
 ACA (Affordable Care Act), 170
 ACIP (Center for Disease Control’s
 Advisory Committee on
 Immunization Practices),
 124–25
 activists, 283–84
 Affordable Care Act (ACA), 170
 American Indian Cancer
 Foundation, 238–39, 240, 297
 Angie (patient, Texas), 168–71
 Australia’s global leadership,
 242–46
- Balogun, Dr. Onyinye, 279, 300
 Barbara (patient, Zimbabwe),
 199–204, 206, 209–10, 211–12
 Beena (patient, Gambia), 47–48
 brachytherapy, 72, 74–77
- Carol (patient, California), 66–69,
 72, 212
 Catholic Medical Association (CMA),
 135
 CDC’s Advisory Committee on
 Immunization Practices (ACIP),
 124–25
 Cervical Cancer Awareness Month,
 32, 286
 Cervivor (support group), 28, 31,
 218, *See also* Tamika Felder
 (founder of Cervivor)
 Cervivor School, 268, 270, 297
 chemoradiation, 30, 77
 chemotherapy, 67, 68, 132, 162–64,
 188
 child marriage, 83–87
 Chinula, Dr. Lameck, 150, 163–64,
 182–84, 185
- CMA (Catholic Medical Association),
 135
 communication about cervical
 screening, 153–55
 computerized tomography (CT), 68,
 184–85, 275
 condom use, 45, 87, 88, 254, 255
 cost of treatment, 77–79
 expense of early cancer
 treatment, 64
 National Health Service (NHS),
 78
 cost-benefit analysis, 36, 78, 115
 CT (computerized tomography), 68,
 184–85, 275
 cultural objections, screening,
 154–56
- data, 159–61
 U.S. guideline updates, 160
 delivery logistics, vaccine, 137–40
 demand/supply
 human papillomavirus (HPV)
 vaccines, 120–24
 Nigeria, 123–24
 Denisa (patient, Czech Republic),
 273, 274–75
 Denmark, information campaign,
 140–42
 developments in cervical cancer
 prevention, 289–92
 disinformation, media impact,
 129–31
 disparities, a disease of, 98–99
 double standards and stigma, 87–89
- Elvia (patient, Haiti), 95, 97–98, 100,
 185
 Emily (patient, Iowa), 73–77
 empowering women, 91
 ENGAGe Teens, 274–75, 298

- equipment scarcity, 184–86
 obstacle to health care, 149–51
 equity-resilient health care, 111–12,
See also inequity
 European Society of Gynaecological
 Oncology (ESGO), 274, 298
 Eve (patient, New York), 279
 excision therapy, 59, 82
 expense of early cancer treatment,
 64
- false negatives, Pap smear testing,
 60
 Felder, Tamika. *See* Tamika Felder
 financial inequity, 107–10
 Florence (patient, Guinea), 85–86,
 89
 Focus on the Family (evangelical
 parachurch), 135, 137
 follow-up treatment, 59, 151–52,
 235
- Garland, Dr. Suzanne, 244
 Gavi (international aid
 organization), 113, 116–18, 298
 gender bias, screening, 156–58
 gender inequity, 204–9
 genders born with female
 reproductive organs, 18
 geographic inequity, 106–7, 113–15
 Global Initiative Against HPV and
 Cervical Cancer (GIAHC), 230,
 298
 government initiatives, 240–46
 Grand Rounds medical educational
 lectures, 23
 grassroots activism, 229–30, *See also*
 Teal Sisters group/Foundation
 Grounds for Health, 236, 237, 299
- high-risk HPV types, 44, 46–47
 HIV. *See* human immunodeficiency
 virus
 HPV. *See* human papillomavirus
 HPV-DNA testing, 42–46, 62–63,
 145–46, 232–36
 human immunodeficiency virus
 (HIV), 18, 80–91
 cervical cancer accelerant, 81–82
 HIV-HPV link, 89–91
 incidence, 80, 83
 PEPFAR (the U.S. President’s
 Emergency Plan for AIDS
 Relief), 90, 234–35
 prevalence, 80, 83
 human papillomavirus (HPV),
 41–49
 high-risk HPV types, 44, 46–47
 HIV-HPV link, 89–91
 HPV doesn’t always equal cancer,
 44–47
 HPV-DNA testing, 42–46, 62–63,
 145–46, 232–36
 HPV-positive patients, 41–49
 HPV-types, 24, 44, 46–47
 oncogenic or high-risk HPV types,
 44, 46–47
 prevalence, 42–49
 sexual transmission, 41–42
 smoking, 45
 stigma, 41–42
 transmission chain, 254–55
 human papillomavirus (HPV)
 vaccines/vaccination, 8, 23–25
 cancer protection, 55–57
 cervical cancer prevention rate,
 24, 114, 123
 demand/supply, 120–24
 effectiveness, 143
 innovations, 231–32
 Koutsky, Dr. Laura, 23
 logistics of vaccine delivery,
 137–40
 marketplace whims, 115–16
 prevention pillar, 51–55
 school-based vaccination, 138–40
 sexual activity and HPV vaccin-
 ation, 216–17
 timing, 52–55
 uptake, 25–27
 WHO recommendations, 8
 Human Rights Watch, 148, 156,
 283–84, 299
 Hutubessy, Dr. Raymond, 36
 hyperbaric oxygen treatment, 73
- Icó (patient, Hungary), 273, 275–76
 immunotherapy, 66

- incidence
 cervical cancer, 58, 66
 human immunodeficiency virus (HIV), 80, 83
- income inequity, 99–100
- income-level categories, 19
- inequity
 financial, 107–10
 gender, 204–6
 geographic, 106–7, 113–15
 income, 99–100
 information, 110–11
 money role, 164–65
 payment, 204–6
 racial, 100–6, 195–96
 ubiquity, 19–22, 27
- information
 Denmark, information
 campaign, 140–42
 disinformation, media impact, 129–31
 fuel for change, 282–85
 good information, 132–34, 140–42
 inequity, 110–11
- innovations
 human papillomavirus (HPV)
 vaccines, 231–32
 screening, 232–36
 treatment, 236–37
- investing in women, 34–36
- Japan, media impact, 128–29
- Jo's Cervical Cancer Trust, 153, 300
- Kampabwe, Dr. Sharon, 246–47
- Karen (patient, Zambia), 224–31, 260
- Karla (patient, Honduras), 269–71
- Kenya Catholic Doctors' Association, 208
- Kenya's County First Ladies Association, 208
- Kim (patient, Cincinnati, Ohio), 95–98
- Kim (patient, Holland), 273–74
- Koutsky, Dr. Laura
 high-risk HPV types, 46–47
- human papillomavirus (HPV)
 vaccines, 23
 oncogenic or high-risk HPV types, 46–47
- LEEP (loop electrosurgical excision procedures), 59, 82
- life lottery, 113–15
 Namibia, 118–20
- Linda (patient, Texas), 190–92
- logistics of vaccine delivery, 137–40
- loneliness, 31
- loop electrosurgical excision procedures (LEEP), 59, 82
- Loretta (patient, California), 251–53
- Mama (patient, Liberia), 178–82
- Maria (patient, Nicaragua), 2–6
- marketplace whims, human papillomavirus (HPV) vaccines, 115–16
- media impact
 disinformation, 129–31
 Japan, 128–29
- Medicaid
 access, 120, 170, 283
 expansion, 170–72
 reduction in support, 107, 109
- Medicare, payment inequity, 204
- men's roles, 250–61
 advocacy, 252–53
 dismantling patriarchy, 258–61
 HPV vaccination, 255–58
 supportive partners, 251–52
 transmission chain, 254–55
- Michele (patient, India), 230–31, 298
- misdiagnosis, 161–64
- Mission-Driven Tech, 300
- money role in inequity, 164–65
- Morgan (patient, Des Moines), 132–34, 172, 271–72
- mortality, cervical cancer, 26–27
- Namibia, life lottery, 118–20
- National Health Service (NHS), cost of treatment, 78
- Navegación de Pacientes Internacional, 301

- NGOs (nongovernmental organizations), 165–68
- NHS (National Health Service), cost of treatment, 78
- Nigeria, demand/supply, 123–24
- Nina. *See* Teolita/Nina
- nongovernmental organizations (NGOs), 165–68
- normal physical appearance, treatment, 74
- obstacles to health care
equipment scarcity, 149–51, 184–86
physical hurdles, 148–49
- obstacles to prevention, 18
stigma, 152–58
systemic bias, 152–58
taboos, 152–58
- obstacles to treatment, 176–98
- oncogenic or high-risk HPV types, 44, 46–47
- Operation Wipe Out, 235, 303
- Organization of African First Ladies for Development, 301
- palliative care, 197–98
- Pap smear testing, 29–30, 60–61,
See also screening
aversion to, 217–18
false negatives, 60
personal experience, 50–52
prevention ‘pillar,’ 51–55
top-tier testing, 60–61
- patriarchy, 199–202, 203–6, 209–12, 214–16, 217–18
dismantling, 258–61
- payment inequity, 204–6
- pelvic examinations, delayed access to, 196
- pelvic exenteration, 67–69
- PEPFAR (the U.S. President’s Emergency Plan for AIDS Relief), 90, 234–35
- personal power, 287
- Planned Parenthood clinics, 108, 132, 172–73, *See also* abortion prevalence
- human immunodeficiency virus (HIV), 80, 83
- human papillomavirus (HPV), 42–49
- preventable cancer, 5–6
statistics, 6
- prevention “pillars,” 51–55
human papillomavirus (HPV) vaccines, 51–55
screening, 51–55
treatment, 55
- prevention scarcity, 64–65
- racial inequity, 100–6, 195–96
- radiation enteritis, 73–77, 78, 96
- radiation treatment, 72–77
chemoradiation, 77
Syed radiation treatment, 74–76
- radiotherapy, 185–88
- RAiSE Foundation, 302
- Ruth (patient, Malawi), 161–64
- SAGE (Strategic Advisory Group of Experts), World Health Organization (WHO), 121–22, 125
- Sally Agallo Kwenda (patient, Kenya), 277–79
- scarcity mindset, screening, 173–75
- school-based vaccination, 138–40
- screening, 57–60, *See also* Pap smear testing
communication about cervical screening, 153–55
cultural objections, 154–56
data, 159–61
equipment scarcity, 149–51, 184–86
follow-up treatment, 59, 151–52, 235
gender bias, 156–58
goal, 173–75
innovations, 232–36
obstacles, 143–75
prevention “pillar,” 51–55
rates, 144–45
scarcity mindset, 173–75
talking openly, 218–20
testing, 58

- WHO pledge, 173
- WHO recommendations, 52
- sea change, 223–24, 248–49
- sexual activity and HPV
 - vaccination, 216–17
- sexual assault victims, 47–48
- sexual stigma, 87–89
- sexual transmission, 135–37
 - human papillomavirus (HPV), 41–42
- smear testing. *See* Pap smear testing
- smoking, 45
- social media
 - disinformation, 129–31
 - Japan, 128–29
- Society of Gynecologic Oncology of Canada, 184
- statistics, preventable cancer, 6
- stigma, 152–58, 192–96, 209–12
 - combating, 277–79
 - double standards, 87–89
 - human papillomavirus (HPV), 41–42, 47–49
 - infertility, 201–2
 - sexual stigma, 87–89
 - stigma-busting, 287
- Stoma World Kenya, 278, 302
- Strategic Advisory Group of Experts (SAGE), World Health Organization (WHO), 121–22, 125
- supply/demand
 - human papillomavirus (HPV) vaccines, 120–24
 - Nigeria, 123–24
- surgery, 188, 200–1
- survivorship, treatment, 76
- Susie (patient, Colorado), 13–17
 - leg swelling, 15, 16
- Syed radiation treatment, 74–76
- systemic bias, 152–58
- taboos, 152–58, 269–71
- talking openly, 218–20
- Tamika Felder (founder of Cervivor), 218, 263–69, 279, *See also* Cervivor (support group)
- Teal Sisters group/Foundation, 226–48, 260, 302
- Teolita/Nina (patient/mother, Georgia), 28–38, 74, 155, 194
- testing. *See also* screening, Pap smear testing, HPV-DNA testing
 - screening step, 58
 - thermal ablation, 59–60, 82, 236
- TogetherHER for Health, 235, 303
- top-tier testing, Pap smear testing, 60–61
- treatment
 - ablation, 59–60, 82, 236
 - Carol (patient, California), 66–69, 72
 - cost, 64, 77–79
 - excision therapy, 59, 82
 - follow-up treatment, 59, 151–52, 235
 - hyperbaric oxygen treatment, 73
 - innovations, 236–37
 - LEEP (loop electrosurgical excision procedures), 59, 82
 - normal physical appearance, 74
 - obstacles to treatment, 176–98
 - pelvic exenteration, 67–69
 - prevention “pillar,” 55
 - radiation treatment, 72–77
 - stages 1 through 4, 69, 71
 - survivorship, 76
 - thermal ablation, 59–60, 82, 236
 - traveling for treatment, 189–92
- unpaid labor, 213–16
- vaccines/vaccination. *See* human papillomavirus (HPV) vaccines/vaccination
- Visual Inspection with Acetic Acid (VIA), 63, 145–46, 147–48, 161–62, 233–35
 - misdiagnosis, Malawi, 161–64
 - Zambia, 246
- voting, 285
- Women 4 Cancer Early Detection & Treatment, 209
- women’s worth, 33–38

336

Index

- working women, 213–16
- World Bank classifications of
 - income levels by country, 19
- World Health Organization (WHO)
 - Cervical Cancer Elimination Initiative, 303
 - HPV vaccine recommendations, 8
 - investing in women, 35–36
 - screening guidelines, 52
 - screening pledge, 173
 - Strategic Advisory Group of Experts (SAGE), 121–22, 125
 - treatment goals, 176
- Zambia’s commitment, 246–48